AstraZeneca Pharma India - Financials, Valuation, Risks & Outlook — Oncology & Cardio-Renal Innovator at Premium Multiples
AstraZeneca Pharma India - Financials, Valuation, Risks & Outlook — Oncology & Cardio-Renal Innovator at Premium Multiples
A
Anjali Anand
No description available.
Latest articles from Anjali Anand
- Industrials
- Apr 27, 2026
- By Anjali Anand
Schneider Electric Infrastructure Share Price
Schneider Electric Infrastructure Share Price
- Industrials
- Apr 27, 2026
- By Anjali Anand
Atlanta Electricals - Transformer Boom, Financials, Valuation & Risks — 125% Profit Growth, 50.2% ROCE at 85.6x Earnings
Atlanta Electricals - Transformer Boom, Financials, Valuation & Risks — 125% Profit Growth, 50.2% ROCE at 85.6x Earnings
- Industrials
- Apr 27, 2026
- By Anjali Anand
Amic Forging Share Price - Specialty Forgings, Financials, Valuation & Risks — 45% Profit Decline, Cash Flow Turns Positive, 70x P/E
Amic Forging Share Price - Specialty Forgings, Financials, Valuation & Risks — 45% Profit Decline, Cash Flow Turns Positive, 70x P/E
- Industrials
- Apr 27, 2026
- By Anjali Anand
Blue Star - AC Market Leader, Financials, Valuation & Risks — 138% OCF Jump, 72x Earnings, Structural India AC Story
Blue Star - AC Market Leader, Financials, Valuation & Risks — 138% OCF Jump, 72x Earnings, Structural India AC Story
- Penny
- Apr 24, 2026
- By Anjali Anand
G R Infraprojects Ltd (GRIL) —Roads EPC & HAM Leader With Vertical Integration, 36% Revenue Growth & Value Valuation at 7.85
G R Infraprojects Ltd (GRIL) —Roads EPC & HAM Leader With Vertical Integration, 36% Revenue Growth & Value Valuation at 7.85